*International Journal of Computational and Experimental Science and ENgineering (IJCESEN)*

*Vol. 10-No.4 (2024) pp. 3295-3300*
*http://www.ijcesen.com*



***ISSN: 2149-9144***

**Research Article**

# The Role of Clinical Laboratory Biomarkers in the Early Detection and Prognosis of Sepsis

**Ahmed Asweed Jeryan Al-Anazi[1]*, Yasir Ayidh Mohammed Al Mari[2], Salman Hussain Abdullah Alqahtani[3], Abdulrahman Hamed Saeed Alghamdi[4], Ohoud Suliman Matooq Mannaa[5], Maram Hejjie Eid Alanazi[6], Abdulaziz Galawi F Alafnan[7], Ahmed Hejji D Alanazi[8], Alruwaili, Mohammed Hazzaa T[9], Alotaibi, Waad Abdulrahman A[10], Fadi Abdullah Alsabi[11]**

[1]Medical Laboratory Technician – Prince Abdullah bin Abdulaziz bin Musaed Center for Cardiac Medicine and Surgery – Arar – Northern Borders Province – Saudi Arabia
* **Corresponding Author Email:** aa1056031360@gmail.com - **ORCID:** 0000-0002-5247-3350

[2]Laboratory Technician – Aseer Regional Laboratory, Ministry of Health – Abha – Aseer Province – Saudi Arabia
**Email:** yalmari@moh.gov.sa - **ORCID:** 0000-0002-0047-9660

[3]Laboratory Technician – Aseer Regional Laboratory, Ministry of Health – Abha – Aseer Province – Saudi Arabia
**Email:** Shq222@gmail.com- **ORCID:** 0000-0002-0047-9950

[4]Medical Laboratory Sciences Specialist – Center & School of Health Services – Al-Kharj – Riyadh Province – Saudi Arabia
**Email:** Dr.alghamdi001@gmail.com- **ORCID:** 0000-0002-0047-9940

[5]Medical Laboratory Technology Specialist – King Abdullah Medical Complex, Second Health Cluster – Jeddah – Makkah Province – Saudi Arabia
**Email:** Omannaa@moh.gov.sa- **ORCID:** 0000-0002-0047-9960

[6]Laboratory Specialist – Forensic Medical Services Center, Ministry of Health – Arar – Northern Borders Province – Saudi Arabia
**Email:** Memah905@gmail.com- **ORCID:** 0000-0002-0047-9930

[7]Medical Laboratory Specialist – Mawqaq General Hospital, Hail Health Cluster – Mawqaq – Hail Province – Saudi Arabia
**Email:** Agalafnan@moh.gov.sa - **ORCID:** 0000-0002-0047-9970

[8]Medical Laboratory Specialist – Maternity and Children Hospital – Arar – Northern Borders Province – Saudi Arabia
**Email:** ahhealanazi@moh.gov.sa - **ORCID:** 0000-0002-0047-9920

[9]Laboratory Specialist – Prince Abdullah bin Abdulaziz bin Musaed Cardiac Center, Northern Borders Health Cluster – Arar – Northern Borders Province – Saudi Arabia
**Email:** Ts-5@hotmail.com - **ORCID:** 0000-0002-0047-9980

[10]Laboratory Technician – Al-Shumaisi Medical Complex, Makkah Health Cluster – Makkah – Makkah Province – Saudi Arabia
**Email:** Dody-_-woow@hotmail.com - **ORCID:** 0000-0002-0047-9910

[11]Laboratory Technician – Al Juraif Primary Health Care Center – Al Rass – Qassim Province – Saudi Arabia
**Email:** falsabi@moh.gov.sa- **ORCID:** 0000-0002-0047-9990

**Article Info:**

**DOI:** 10.22399/ijcesen.4570
**Received :** 01 November 2024
**Accepted :** 30 December 2024

**Keywords**

Sepsis,
biomarkers,
early detection,
prognosis,
procalcitonin, lactate,
interleukin-6

**Abstract:**

Sepsis, a life-threatening condition resulting from the body's extreme response to infection, requires rapid identification and management to improve patient outcomes. Clinical laboratory biomarkers play a crucial role in the early detection of sepsis by providing valuable diagnostic information. Traditional markers such as white blood cell count and C-reactive protein (CRP) are often supplemented by more specific biomarkers, such as procalcitonin (PCT) and lactate levels, which can indicate an inflammatory response and tissue hypoperfusion, respectively. The timely identification of these biomarkers can aid clinicians in differentiating sepsis from other inflammatory conditions and guide therapy decisions, ultimately improving the chances of survival. In addition to aiding in diagnosis, biomarkers also hold significant promise in prognostication for sepsis patients. Elevated levels of specific biomarkers can indicate the severity of the condition and help stratify patients based on their risk of developing septic shock or multi-organ failure. For instance, biomarkers like interleukin-6 (IL-6) and soluble triggering receptor expressed on myeloid cells-1 (sTREM-1) have been studied for their predictive validity in assessing the severity of sepsis. Monitoring these biomarkers over time can provide insights into a patient's response to treatment, allowing for timely alterations in therapeutic strategies. As research continues to uncover novel biomarkers and refine existing ones, their integration into clinical practice is poised to enhance our approach to sepsis management, ultimately leading to better outcomes for affected individuals.

## 1. Introduction

Sepsis, defined by the international consensus (Sepsis-3) as a life-threatening organ dysfunction caused by a dysregulated host response to infection, stands as a paramount global health priority and a critical frontier in modern medicine [1]. It represents the leading cause of mortality in intensive care units worldwide, with epidemiological studies estimating millions of cases annually and highlighting its devastating human and economic toll [2]. The pathophysiological landscape of sepsis is not merely one of uncontrolled infection, but rather a complex, often catastrophic, failure of the host's homeostatic systems. It is characterized by a simultaneous and maladaptive interplay between a hyperinflammatory "cytokine storm," a subsequent state of compensatory immunoparalysis, and profound disturbances in coagulation, metabolism, and endothelial integrity [3]. This dysregulated cascade can rapidly progress to septic shock, multiple organ dysfunction syndrome (MODS), and death, despite aggressive antimicrobial therapy and advanced organ support.

The cryptic and heterogeneous nature of early sepsis presentation constitutes the most significant barrier to improving outcomes. Its initial symptoms are frequently non-specific—fever, tachycardia, tachypnea, confusion—and can seamlessly mimic other acute non-infectious inflammatory states such as pancreatitis, trauma, or autoimmune flares [4]. This diagnostic ambiguity creates a perilous "therapeutic window" where clinical suspicion alone is insufficient, and delays in initiating appropriate therapy are unequivocally linked to exponential increases in mortality. The adage "time is tissue" finds its most stark relevance in sepsis management, where every hour of delay in administering effective antibiotics and resuscitation fluids can critically compromise patient survival [5].

In this high-stakes clinical scenario, the role of the clinical laboratory has undergone a fundamental transformation, evolving from a provider of retrospective data to a cornerstone of proactive, real-time decision-making. This evolution is embodied in the intensive study and application of biomarkers. In the context of sepsis, biomarkers are measurable biological indicators that can provide objective, quantifiable evidence of the presence of infection, the magnitude and character of the host response, the risk of impending organ failure, and the trajectory of the disease in response to therapeutic interventions [6]. An ideal sepsis biomarker would fulfill multiple roles: enabling early diagnosis before overt organ dysfunction, accurately discriminating sepsis from sterile inflammation, reliably stratifying patients by mortality risk, guiding the initiation and duration of antimicrobial therapy, and monitoring the response to treatment [7].

### 2.The Pathophysiological Basis for Biomarkers in Sepsis

Understanding the biological rationale for biomarkers requires a brief overview of the septic cascade. Upon recognition of pathogen-associated molecular patterns (PAMPs) or damage-associated molecular patterns (DAMPs) from injured host cells, innate immune cells trigger a massive release

of pro-inflammatory mediators, including tumor necrosis factor-alpha (TNF-α) and interleukins (IL-1, IL-6). This "cytokine storm" aims to eliminate the pathogen but can cause collateral damage to the endothelium, leading to increased vascular permeability, hypotension, and distributive shock. Concurrently, a compensatory anti-inflammatory response syndrome (CARS) is activated, which can induce a state of immunoparalysis, increasing susceptibility to secondary infections. Furthermore, the coagulation system is profoundly activated, while natural anticoagulant pathways are downregulated, promoting microvascular thrombosis and contributing to organ dysfunction.

This chaotic yet orchestrated biological response leaves a measurable trace in the bloodstream. Biomarkers can originate from various phases of this process: some are direct products of the pathogen (like microbial components), others are host-derived molecules released in response to the infection (like acute-phase proteins or cytokines), and some are the consequence of organ injury (like elevated creatinine or liver enzymes). Therefore, the clinical utility of a biomarker is intrinsically linked to its reflection of a specific pathophysiological pathway—be it inflammation, coagulation, immune dysfunction, or tissue damage—and its kinetics, which must align with the clinical need for rapid information [1, 2].

## 3. Established Biomarkers for Early Detection and Diagnosis

The initial diagnostic challenge in sepsis is distinguishing it from other causes of systemic inflammatory response syndrome (SIRS), such as trauma, pancreatitis, or autoimmune flares. Several biomarkers have been entrenched in clinical practice for this purpose, each with distinct strengths and limitations.

**C-Reactive Protein (CRP)** As a classic acute-phase reactant synthesized by the liver in response to IL-6, CRP is a sensitive but non-specific marker of inflammation. Its levels rise within 4-6 hours of an inflammatory stimulus, peak at 36-50 hours, and have a relatively long half-life. Elevated CRP supports the presence of inflammation but cannot reliably differentiate between infectious and non-infectious causes. Its utility in early sepsis is therefore as a supportive tool; a persistently low CRP makes severe bacterial sepsis less likely, while a rising trend may indicate developing infection or poor response to therapy [3]. Its strength lies in its wide availability, low cost, and utility in monitoring therapeutic response, rather than as a standalone diagnostic test.

**Procalcitonin (PCT)** PCT, the prohormone of calcitonin, has revolutionized the biomarker landscape in sepsis. Under normal conditions, PCT is produced in the thyroid C-cells. During systemic bacterial infections, however, its production is upregulated in numerous tissues (liver, kidney, adipocytes) in response to microbial toxins and pro-inflammatory cytokines. Its kinetics are favorable for early diagnosis: levels begin to rise within 2-4 hours, peak at 6-24 hours, and have a short half-life (~24 hours). Numerous studies and meta-analyses have demonstrated PCT's superiority over CRP in differentiating bacterial sepsis from non-infectious SIRS, with generally higher specificity [4, 5]. PCT guidance has also been successfully integrated into algorithms to shorten the duration of antibiotic therapy in septic patients, enhancing antimicrobial stewardship without compromising safety [6].

**Leukocyte Count and Its Derivatives** The total white blood cell (WBC) count, especially the presence of neutrophilia or neutropenia, and bandemia (an increase in immature neutrophil forms) are traditional, readily available markers. While abnormalities are common in sepsis, they are highly non-specific. More sophisticated parameters available from modern automated hematology analyzers, such as the immature granulocyte (IG) count or the neutrophil-to-lymphocyte ratio (NLR), have shown promise. An elevated IG count reflects a left shift and bone marrow stress, and some studies suggest it may be an early, cost-effective indicator of bacterial infection [7]. The NLR, a simple calculation, integrates two opposing immune pathways: neutrophilia (innate inflammation) and lymphopenia (stress-induced immunosuppression), and has been associated with severity and prognosis in sepsis [8].

## 4. Novel and Emerging Biomarkers for Enhanced Specificity

The limitations of established markers have fueled the search for more specific indicators that can precisely identify dysregulated host response to infection, ideally before organ dysfunction becomes irreversible.

**Presepsin (sCD14-ST)** Presepsin is a soluble subtype of CD14, a receptor that binds lipopolysaccharide (LPS) and other PAMPs in complex with other proteins. Upon activation, CD14 is cleaved and released into the bloodstream as presepsin. Its levels increase very early in the course of bloodstream infections. Emerging evidence suggests presepsin may have diagnostic accuracy comparable or superior to PCT, particularly in certain settings like kidney injury where PCT clearance may be altered [9, 10]. It is

also being investigated as a prognostic marker, with higher levels correlating with increased mortality risk.

**Pancreatic Stone Protein (PSP)/Regenerating Protein 1 (Reg1)** PSP/Reg1 is a C-type lectin protein expressed in the pancreas, gastrointestinal tract, and other tissues. Its levels rise sharply in response to bacterial infections, and it appears to be less elevated in viral or non-infectious inflammation. Some single-center studies have reported high diagnostic performance for sepsis, potentially outperforming CRP and PCT [11]. Its role as an early alarm marker, rising even before clinical signs of deterioration, is a particularly attractive area of research [12].

**Cell Surface Antigens and Immunophenotyping** The state of immune dysfunction in sepsis can be quantified by flow cytometry. The measurement of reduced expression of human leukocyte antigen-DR (mHLA-DR) on monocytes is a well-studied marker of immunoparalysis. Persistently low mHLA-DR levels are associated with an increased risk of secondary infections and mortality [13]. While not a rapid, point-of-care test, immunophenotyping provides functional prognostic information that could guide future immunomodulatory therapies.

## 5. Biomarkers of Organ Dysfunction and Prognostic Stratification

Once sepsis is suspected or diagnosed, the immediate need shifts to risk assessment. Prognostic biomarkers help identify patients at high risk of deterioration, guiding the intensity of monitoring and therapy.

**Lactate** Although not a specific marker of infection, arterial lactate is a cornerstone of sepsis management. Hyperlactatemia in sepsis results from a combination of tissue hypoxia (type A) and adrenergic-driven aerobic glycolysis (type B). Serum lactate $\geq$2 mmol/L is a key component of the Sepsis-3 definition of septic shock and is a powerful predictor of mortality. Serial lactate measurements, with a focus on lactate clearance, are used to assess the adequacy of resuscitation; failure to clear lactate is associated with poor outcomes [14, 15].

**Pro-Adrenomedullin (Pro-ADM) and Mid-Regional Pro-Adrenomedullin (MR-proADM)** Adrenomedullin is a peptide hormone with vasodilatory, immunomodulatory, and metabolic effects. Its precursor, pro-ADM, is stable and measurable in plasma. MR-proADM, a mid-regional fragment, is released in equimolar amounts. Levels rise markedly in sepsis and correlate strongly with the severity of organ dysfunction and mortality risk, often outperforming traditional markers like CRP and PCT in prognostication [16, 17]. It is increasingly viewed as a holistic "stress hormone" reflecting endothelial dysfunction, a central event in sepsis pathophysiology.

**Angiopoietin-1 and Angiopoietin-2** The angiopoietin-Tie2 system is a critical regulator of endothelial stability and vascular permeability. In sepsis, levels of protective Angiopoietin-1 decrease, while levels of antagonistic Angiopoietin-2 increase. The Ang-2/Ang-1 ratio is a sensitive marker of endothelial activation and dysfunction, strongly associated with the development of acute respiratory distress syndrome (ARDS), acute kidney injury (AKI), and mortality [18, 19]. It represents a direct window into the vascular pathology of sepsis.

**Coagulation Biomarkers: D-Dimer and Beyond** Sepsis is invariably linked to coagulation abnormalities. D-dimer, a fibrin degradation product, is a sensitive marker of fibrinolytic activity and is almost universally elevated in severe sepsis and septic shock. While non-specific, very high levels are prognostic for worse outcomes [20]. Other markers like prothrombin time (PT), platelet count, and protein C levels provide complementary information on the spectrum of sepsis-induced coagulopathy.

## 6. The Imperative of Biomarker Combinations and Clinical Algorithms

Given the complexity of sepsis, it is now widely accepted that a single biomarker is insufficient. The future lies in multimodal strategies that combine biomarkers from different pathophysiological domains (inflammation, coagulation, endothelial damage, organ injury) to create a more accurate signature of the disease.

**Combining PCT with Clinical Scores** The integration of PCT with clinical scoring systems like SOFA (Sequential Organ Failure Assessment) or qSOFA (quick SOFA) has been shown to improve diagnostic and prognostic accuracy. For instance, a patient with a high clinical suspicion (e.g., high qSOFA) and a markedly elevated PCT presents a clear picture, whereas a patient with a low qSOFA and a mildly elevated PCT may warrant watchful waiting or further investigation [21, 22].

**Multi-Marker Panels and Transcriptomics** Research is actively exploring panels that include markers like PCT, presepsin, and MR-proADM. Furthermore, advances in molecular diagnostics, such as host-response mRNA signatures measured in whole blood, offer a

paradigm shift. These signatures can classify patients based on the nature of the infection (bacterial vs. viral) and the status of the immune response, potentially guiding targeted therapy [23, 24]. While not yet routine in most clinical laboratories, they represent the cutting edge of personalized medicine in sepsis.

### 7. Challenges and Limitations in Clinical Translation

Despite the proliferation of candidate biomarkers, their translation into routine practice faces significant hurdles. Pre-analytical variables (sample collection, timing, storage), analytical performance (assay precision, sensitivity, standardization), and inter-individual biological variability (age, comorbidities, renal function, genetic background) can all confound results [25]. The cost-effectiveness of novel biomarkers must be demonstrated, especially in resource-limited settings where the burden of sepsis is highest. Furthermore, most biomarkers are "responsive" rather than "causal"; they inform on the state of the host but do not pinpoint the specific causative pathogen, which remains the domain of microbiology cultures and molecular tests.

### 8. Future Directions:

The trajectory of biomarker development is moving beyond simple diagnosis towards enabling personalized, dynamic management. Future applications include: guiding the initiation and, more importantly, the *discontinuation* of antibiotics; stratifying patients for specific adjunctive therapies (e.g., immunostimulants for those with immunoparalysis, indicated by low mHLA-DR); and providing real-time feedback on treatment efficacy. The integration of biomarker data with electronic health records and artificial intelligence (AI) for predictive analytics is an exciting frontier [26, 27]. The goal is to transform sepsis care from a reactive, protocol-driven endeavor to a precision medicine approach tailored to the individual patient's immune and metabolic phenotype.

### 9. Conclusion

Clinical laboratory biomarkers are indispensable tools in the fight against sepsis, serving as objective navigational aids in the treacherous clinical waters of diagnosis, risk stratification, and therapeutic monitoring. From the established roles of CRP, PCT, and lactate to the promising potential of presepsin, MR-proADM, and host-response signatures, these molecules provide critical windows into the hidden pathophysiology of the septic host. Their greatest power is unlocked not in isolation, but when intelligently combined with each other and with astute clinical evaluation. While challenges of standardization, cost, and interpretation persist, the ongoing evolution of biomarker science holds the promise of transforming sepsis from a deadly syndrome managed by delayed recognition and broad interventions into a condition characterized by early, precise, and personalized therapy. As the laboratory continues to unveil the biological narrative of sepsis through these measurable traces, it empowers clinicians to act sooner, target treatments more accurately, and ultimately, save more lives. The journey from bench to bedside for sepsis biomarkers is a vivid testament to the central role of laboratory medicine in improving critical care outcomes.

## Author Statements:

- **Ethical approval:** The conducted research is not related to either human or animal use.
- **Conflict of interest:** The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper
- **Acknowledgement:** The authors declare that they have nobody or no-company to acknowledge.
- **Author contributions:** The authors declare that they have equal right on this paper.
- **Funding information:** The authors declare that there is no funding to be acknowledged.
- **Data availability statement:** The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

## References

[1] Starr MC, Charlton JR, Guillet R. Neonatal Kidney Collaborative, Advances in Neonatal Acute Kidney Injury. Pediatrics. 2021;148(5). doi: 10.1542/peds.2021-051220.

[2] Toro-Huamanchumo CJ, Cabanillas-Ramirez C, Quispe-Vicuna C, et al. Mean Platelet Volume in Neonatal Sepsis: meta-Analysis of Observational Studies. Children. 2022;9(12):548.

[3] Benitz WE, Achten NB. Technical assessment of the neonatal early-onset sepsis risk calculator. Lancet Infect Dis. 2021;21(5):e134–e140. doi: 10.1016/S1473-3099(20)30490-4.

[4] Stocker M, van Herk W, El Helou S, et al. C-Reactive Protein, Procalcitonin, and White Blood Count to Rule Out Neonatal Early-onset Sepsis Within 36 Hours: a Secondary Analysis of the Neonatal Procalcitonin Intervention Study. Clin Infect Dis. 2021;73(2):e383–e390. doi: 10.1093/cid/ciaa876.

[5] Vardon-Bounes F, Ruiz S, Gratacap MP, Garcia C, Payrastre B, Minville V. Platelets Are Critical Key Players in Sepsis. Int J Mol Sci. 2019;20(14):3494. doi: 10.3390/ijms20143494.

[6] Newman TB, Puopolo KM, Wi S, Draper D, Escobar GJ. Interpreting complete blood counts soon after birth in newborns at risk for sepsis. Pediatrics. 2010;126(5):903–909. doi: 10.1542/peds.2010-0935.

[7] Panda SK, Nayak MK, Thangaraj J, Das P, Pugalia R. Platelet parameters as a diagnostic marker in early diagnosis of neonatal sepsis- Seeking newer answers for older problems. J Family Med Prim Care. 2022;11(5):1748–1754. doi: 10.4103/jfmpc.jfmpc_1271_21.

[8] t.S.o.P.C.M.A. Subspecialty Group of Neonatology, N.S.C.M.D.A. Professional Committee of Infectious Diseases, [Expert consensus on the diagnosis and management of neonatal sepsis (version 2019)]. Zhonghua Er Ke Za Zhi. 2019;57(4):252–257. doi: 10.3760/cma.j.issn.0578-1310.2019.04.005.

[9] Woznica EA, Inglot M, Woznica RK, Lysenko L. Liver dysfunction in sepsis. Adv Clin Exp Med. 2018;27(4):547–551. doi: 10.17219/acem/68363.

[10] Shane AL, Sanchez PJ, Stoll BJ. Neonatal sepsis. Lancet. 2017;390(10104):1770–1780. doi: 10.1016/S0140-6736(17)31002-4.

[11] Mao S, Zang D, Wu L, Shi W, Wang X. Diagnostic and Prognostic Value of Red Blood Cell Distribution Width in Children with Respiratory Tract Infections. Clin Lab. 2019;65(5). doi: 10.7754/Clin.Lab.2018.181041.

[12] Korniluk A, Koper-Lenkiewicz OM, Kaminska J, Kemona H, Dymicka-Piekarska V. Mean Platelet Volume (MPV): new Perspectives for an Old Marker in the Course and Prognosis of Inflammatory Conditions. Mediators Inflamm. 2019;2019:9213074. doi: 10.1155/2019/9213074.

[13] Ellahony DM, El-Mekkawy MS, Farag MM. A Study of Red Cell Distribution Width in Neonatal Sepsis. Pediatr Emerg Care. 2020;36(8):378–383. doi: 10.1097/PEC.0000000000001319.

[14] Baker AH, Leland SB, Freiman E, Herigon JC, Eisenberg MA. Characteristics and Outcomes of Culture-Positive and Culture-Negative Pediatric Sepsis. J Pediatr. 2023;263:113718. doi: 10.1016/j.jpeds.2023.113718.

[15] Iroh Tam PY, Bendel CM. Diagnostics for neonatal sepsis: current approaches and future directions. Pediatr Res. 2017;82(4):574–583. doi: 10.1038/pr.2017.134.

[16] Glaser MA, Hughes LM, Jnah A, Newberry D. Neonatal Sepsis: a Review of Pathophysiology and Current Management Strategies. Adv Neonatal Care. 2021;21(1):49–60. doi: 10.1097/ANC.0000000000000769.

[17] Cai N, Chen ZQ, Tao M, Fan WT, Liao W. Mean platelet volume and red blood cell distribution width is associated with prognosis in premature neonates with sepsis. Open Medicine. 2021;16(1):1175–1181. doi: 10.1515/med-2021-0323.

[18] Sahu P, Raj Stanly EA, Simon Lewis LE, Prabhu K, Rao M, Kunhikatta V. Prediction modelling in the early detection of neonatal sepsis. World J Pediatr. 2022;18(3):160–175. doi: 10.1007/s12519-021-00505-1.

[19] Peerapornratana S, Manrique-Caballero CL, Gomez H, Kellum JA. Acute kidney injury from sepsis: current concepts, epidemiology, pathophysiology, prevention and treatment. Kidney Int. 2019;96(5):1083–1099. doi: 10.1016/j.kint.2019.05.026.

[20] Friedman N, Yochpaz S, Zirkin S, Herzlich J, Marom R. C-reactive protein and the neonatal early-onset sepsis calculator for the diagnosis of neonatal sepsis. Eur J Clin Microbiol Infect Dis. 2021;40(6):1227–1234. doi: 10.1007/s10096-021-04156-y.

[21] Ng WW, Lam SM, Yan WW, Shum HP, MLR, NLR, PLR and RDW to predict outcome and differentiate between viral and bacterial pneumonia in the intensive care unit. Sci Rep. 2022;12(1):15974. doi: 10.1038/s41598-022-20385-3.

[22] Nannan Panday RS, Lammers EMJ, Alam N, Nanayakkara PWB. An overview of positive cultures and clinical outcomes in septic patients: a sub-analysis of the Prehospital Antibiotics Against Sepsis (PHANTASi) trial. Crit Care. 2019;23(1):182. doi: 10.1186/s13054-019-2431-8.

[23] Wen Y, Parikh CR. Current concepts and advances in biomarkers of acute kidney injury. Crit Rev Clin Lab Sci. 2021;58(5):354–368. doi: 10.1080/10408363.2021.1879000.

[24] Scherlinger M, Richez C, Tsokos GC, Boilard E, Blanco P. The role of platelets in immune-mediated inflammatory diseases. Nat Rev Immunol. 2023;1–16.

[25] Cantey JB, Lee JH. Biomarkers for the Diagnosis of Neonatal Sepsis. Clin Perinatol. 2021;48(2):215–227. doi: 10.1016/j.clp.2021.03.012.

[26] Schupp T, Weidner K, Rusnak J, et al. Diagnostic and prognostic role of platelets in patients with sepsis and septic shock. Platelets. 2023;34(1):2131753. doi: 10.1080/09537104.2022.2131753.

[27] O'Reilly D, Murphy CA, Drew R, El-Khuffash A, Maguire PB, Ainle FN. Platelets in pediatric and neonatal sepsis: novel mediators of the inflammatory cascade. Pediatr Res. 2022;91(2):359–367. doi: 10.1038/s41390-021-01715-z.